{"id":"NCT00736099","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM","officialTitle":"A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 1356 (5 mg) as Monotherapy or in Combination With Other Antidiabetic Medications in Type 2 Diabetic Patients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2010-12","completion":null,"firstPosted":"2008-08-15","resultsPosted":"2012-03-08","lastUpdate":"2014-06-27"},"enrollment":2122,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"linagliptine 5 mg","otherNames":[]},{"type":"DRUG","name":"linagliptine 5 mg and pioglitazone 30 mg","otherNames":[]}],"arms":[{"label":"linagliptin 5 mg","type":"EXPERIMENTAL"},{"label":"linagliptin 5 mg and pioglitazone 30 mg","type":"EXPERIMENTAL"}],"summary":"The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.\n\nThe treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)","primaryOutcome":{"measure":"Frequency of Patients With Adverse Events (AEs)","timeFrame":"78 weeks","effectByArm":[{"arm":"Old Lina","deltaMin":1253,"sd":null},{"arm":"New Lina","deltaMin":465,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":232,"countries":["United States","Argentina","Austria","Belgium","Canada","China","Croatia","Czechia","Finland","Germany","Greece","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Philippines","Poland","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":158,"n":1532},"commonTop":["Hyperglycaemia","Hypoglycaemia","Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection"]}}